ExpreS2ion Biotech Holding AB (OSTO:EXPRS2) Profitability Rank: 1 (As of Mar. 2026) — 50% Below Median

Author: Vera Yuan Vera Yuan
Vera Yuan
Vera Yuan
Director of Data and Quant Analytics at GuruFocus
Focused on building reliable datasets, financial models, and research tools for value-minded investors. Committed to turning complex data into practical guidance for value-investing and long-term wealth.
Reviewed by: Charlie Tian Charlie Tian
Charlie Tian
Charlie Tian
Founder & CEO of GuruFocus
Dr. Charlie Tian is the founder and CEO of GuruFocus.com, a leading global investment research platform established in 2004. With a Ph.D. in physics, Dr. Tian transitioned from science to finance, applying a data-driven, disciplined approach to value investing.

OSTO:EXPRS2 ExpreS2ion Biotech Holding AB OSTO:EXPRS2
43 GF Score
Price kr1.45
GF Value kr3.37
Valuation Possible Value Trap
! 5 Warning Signs
View Full Analysis

What is ExpreS2ion Biotech Holding AB Profitability Rank?

ExpreS2ion Biotech Holding AB OSTO:EXPRS2 -1.03% 43 Profitability Rank is 1 as of Mar. 2026, which is 50% below its 10-year median of 2.00. GuruFocus rates OSTO:EXPRS2 with a GF Score™ of 43/100 and a GF Value™ of kr3.37 (Possible Value Trap). The stock has 5 warning signs investors should review.

ExpreS2ion Biotech Holding AB has the Profitability Rank of 1. It has had trouble to make a profit.

GuruFocus Profitability Rank ranks how profitable a company is and how likely the company's business will stay that way. It is rated on a scale of 1 to 10 and is based on these factors:

1. Operating Margin %
2. Piotroski F-Score
3. Trend of the Operating Margin % (5-year average). The company with an uptrend profit margin has a higher rank.
4. Consistency of the profitability
5. Predictability Rank

A higher score indicates superior profitability, with companies rated 7 or above considered to have more robust and sustainable profit generation. Conversely, a score of 3 or lower suggests challenges in generating consistent profits.

ExpreS2ion Biotech Holding AB's Operating Margin % for the quarter that ended in Mar. 2026 was -1,150.39%. As of today, ExpreS2ion Biotech Holding AB's Piotroski F-Score is 3.


ExpreS2ion Biotech Holding AB Profitability Rank Related Terms


OSTO:EXPRS2 vs VRTX, REGN, RVMD: Profitability Rank Comparison

For the Biotechnology subindustry, ExpreS2ion Biotech Holding AB's Profitability Rank, along with its competitors' market caps and Profitability Rank data, can be viewed below:

* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.


ExpreS2ion Biotech Holding AB Profitability Rank vs Biotechnology Industry

For the Biotechnology industry and Healthcare sector, ExpreS2ion Biotech Holding AB's Profitability Rank distribution charts can be found below:

* The bar in red indicates where ExpreS2ion Biotech Holding AB's Profitability Rank falls into.


OSTO:EXPRS2
43GF Score
ExpreS2ion Biotech Holding AB OSTO:EXPRS2
Profitability Rank is just one metric. See GF Score™, valuation, warning signs, and more.
View Full Analysis

ExpreS2ion Biotech Holding AB Profitability Rank Calculation

GuruFocus Profitability Rank ranks how profitable a company is and how likely the company's business will stay that way.

The rank is rated on a scale of 1 to 10. A higher score indicates superior profitability, with companies rated 7 or above considered to have more robust and sustainable profit generation. Conversely, a score of 3 or lower suggests challenges in generating consistent profits.

ExpreS2ion Biotech Holding AB has the Profitability Rank of 1. It has had trouble to make a profit.

Profitability Rank is not directly related to the Financial Strength. But if a company is consistently profitable, its financial strength will be stronger.

Profitability Rank is based on these factors:

1. Operating Margin %

Operating Margin % - also known as operating income margin, operating profit margin and return on sales (ROS) - is the ratio of Operating Income divided by net sales or Revenue, usually presented in percent.

ExpreS2ion Biotech Holding AB's Operating Margin % for the quarter that ended in Mar. 2026 is calculated as:

Operating Margin %=Operating Income (Q: Mar. 2026 ) / Revenue (Q: Mar. 2026 )
=-11.941 / 1.038
=-1,150.39 %

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

2. Piotroski F-Score

Warning Sign:

Piotroski F-Score of 3 is low, which usually implies poor business operation.

The zones of discrimination were as such:

Good or high score = 8 or 9
Bad or low score = 0 or 1

ExpreS2ion Biotech Holding AB has an F-score of 3. It is a bad or low score, which usually implies poor business operation.

3. Trend of the Operating Margin % (5-year average). The company with an uptrend profit margin has a higher rank.

Warning Sign:

ExpreS2ion Biotech Holding AB operating margin has been in a 5-year decline. The average rate of decline per year is -26.6%.

4. Consistency of the profitability

5. Predictability Rank

Frequently Asked Questions Learn more about Profitability Rank →
What does a Profitability Rank of 1 mean?
ExpreS2ion Biotech Holding AB (OSTO:EXPRS2) has a Profitability Rank of 1 as of Mar. 2026. Profitability and Growth ranks a company based on its profit margins and earnings growth. View historical data on ExpreS2ion Biotech Holding AB and its competitors. This is 50% below median its historical median of 2.00. Over the past decade, ExpreS2ion Biotech Holding AB's Profitability Rank has ranged from 1.00 to 3.00.
Is ExpreS2ion Biotech Holding AB's Profitability Rank too high?
ExpreS2ion Biotech Holding AB's current Profitability Rank of 1 is 50% below median its 10-year median of 2.00. Over the past 10 years, this metric has ranged from a low of 1.00 to a high of 3.00. Overall, ExpreS2ion Biotech Holding AB has a GF Score™ of 43/100 and is considered Possible Value Trap, reflecting its overall financial health beyond just this single metric.
How does ExpreS2ion Biotech Holding AB's Profitability Rank compare to VRTX and REGN?
ExpreS2ion Biotech Holding AB's Profitability Rank of 1 can be compared against companies in the Biotechnology industry. Historically, ExpreS2ion Biotech Holding AB's own Profitability Rank has ranged from 1.00 to 3.00 over the past decade. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good Profitability Rank for a Biotechnology company?
A good Profitability Rank depends on the Biotechnology industry context. However, Profitability Rank should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high Profitability Rank mean?
A high Profitability Rank can signal that a stock is expensive relative to its fundamentals. Profitability and Growth ranks a company based on its profit margins and earnings growth. View historical data on ExpreS2ion Biotech Holding AB and its competitors. ExpreS2ion Biotech Holding AB's current Profitability Rank is 1, which is 50% below median its own 10-year median of 2.00. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is ExpreS2ion Biotech Holding AB stock overvalued right now?
Based on GuruFocus' analysis, ExpreS2ion Biotech Holding AB (OSTO:EXPRS2) is currently considered Possible Value Trap. The stock's GF Value™ is kr3.37, compared to a current price of kr1.45 — trading 57.1% below its estimated fair value. The current Profitability Rank is 1, which is 50% below median its 10-year median of 2.00. ExpreS2ion Biotech Holding AB's overall GF Score™ is 43/100 with 5 warning signs to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is Profitability Rank calculated?
Profitability Rank is calculated from a company's financial statements. For ExpreS2ion Biotech Holding AB (OSTO:EXPRS2), the current Profitability Rank is 1 as of Mar. 2026. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.

Is ExpreS2ion Biotech Holding AB (OSTO:EXPRS2) Overvalued in 2026?

Based on GuruFocus' analysis, ExpreS2ion Biotech Holding AB stock appears to be undervalued. The current stock price of kr1.45 is trading 57.1% below its estimated GF Value™ of kr3.37. GuruFocus considers ExpreS2ion Biotech Holding AB to be Possible Value Trap.

Key valuation signals for OSTO:EXPRS2:

  • Profitability Rank: 1 (50% below median its 10-year median of 2.00)
  • GF Value™: kr3.37 vs. price of kr1.45 (57.1% below fair value)
  • GF Score™: 43/100 with 5 warning signs

No single metric tells the full story. See the OSTO:EXPRS2 stock analysis page for a complete view including 30-year financials, guru trades, and insider activity.


ExpreS2ion Biotech Holding AB Business Description

Other Exchanges 5JD0:Germany
Address c/o Mindpark, Ronnowsgatan 8c, Helsingborg, SWE, 252 25
ExpreS2ion Biotech Holding AB is a biotechnology company that develops vaccines. It has developed a human clinical Phase III-validated technology platform, ExpreS2, for fast and efficient development and production of the active material in vaccines. The platform, under the brand GlycoX-S2, includes functionally modified glycosylation variants for enhanced immunogenicity and pharmacokinetics. Its product pipeline comprises ES2B-C001, a HER2-VLP-based vaccine in development for human breast cancer therapy and several exploratory vaccine projects targeting pathways validated by commercial monoclonal antibody products. Geographically, the company operates in the Nordics region and also has a presence in other countries.
43GF Score

Get the complete analysis for OSTO:EXPRS2

Profitability Rank is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.

kr1.45
Price
kr3.37
GF Value